In a series of experiments between 1960 and 1965, Robert Geoffrey Edwards discovered how to make mammalian egg cells, or oocytes, mature outside of a female's body. Edwards, working at several research institutions in the UK during this period, studied in vitro fertilization (IVF) methods. He measured the conditions and timings for in vitro (out of the body) maturation of oocytes from diverse mammals including mice, rats, hamsters, pigs, cows, sheep, and rhesus monkeys, as well as humans. By 1965, he manipulated the maturation of mammalian oocytes in vitro, and discovered that the maturation process took about the same amount of time as maturation in the body, called in vivo. The timing of human oocyte maturation in vivo, extrapolated from Edwards's in vitro study, helped researchers calculate the timing for surgical removal of human eggs for IVF.

Advanced Cell Technology, Inc. (ACT) is a biotechnology company that uses stem cell technology to develop novel therapies in the field of regenerative medicine. Formed in 1994, ACT grew from a small agricultural cloning research facility located in Worcester, Massachusetts, into a multi-locational corporation involved in using both human embryonic stem cells (hESC) and human adult stem cells as well as animal cells for therapeutic innovations. Through its work in developing alternative methods for hESC derivation and its public statements, ACT has also played an active role in stimulating and participating in public debate over stem cell research.

In September 1979, China's Fifth National People's Congress passed a policy that encouraged one-child families. Following this decision from the Chinese Communist Party (CCP), campaigns were initiated to implement the One-Child Policy nationwide. This initiative constituted the most massive governmental attempt to control human fertility and reproduction in human history. These campaigns prioritized reproductive technologies for contraception, abortion, and sterilization in gynecological and obstetric medicine, while downplaying technologies related to fertility treatment. In the late 1980s, one of the consequences was the reorientation of the rationality of governmental funding for research on human in vitro fertilization (IVF) and embryo transfer.

Robert Geoffrey Edwards, a British developmental biologist at University of Cambridge, began exploring human in vitro fertilization (IVF) as a way to treat infertility in 1960. After successfully overcoming the problem of making mammalian oocytes mature in vitro in 1965, Edwards began to experiment with fertilizing matured eggs in vitro. Collaborating with other researchers, Edwards eventually fertilized a human egg in vitro in 1969. This was a huge step towards establishing human IVF as a viable fertility treatment. During the four years in which Edwards experimented with IVF, he experienced many setbacks. These failures in fertilizing oocytes in vitro, however, contributed to the understanding of how fertilization did or did not happen, which was sometimes different from established dogmas. Edwards also collaborated with gynecologist and surgeon Patrick Christopher Steptoe to study sperm capacitation, which became the overture that heralded a series of successes for the team, culminating in the generation of the first test-tube baby Louise Joy Brown in 1978.

The biomedical accomplishment of human in vitro fertilization and embryo transfer (IVF-ET) took years to become the successful technique that presently enables infertile couples to have their own children. In 1969, more than ten years after the first attempts to treat infertilities with IVF technologies, the British developmental biologist Robert Geoffrey Edwards fertilized human oocytes in a Petri dish for the first time. In 1970, Edwards and his research partner, gynecologist and surgeon Patrick Christopher Steptoe, started working with human patients with complicated and individualized gynecological conditions. It took Edwards and Steptoe another eight years of modifying medical procedures, as well as dealing with the ups and downs of funding situations and public opinions, before they could celebrate birth of the first baby conceived through IVF-ET in 1978.

Zhang Lizhu is a Chinese gynecologist and researcher. For most of her career, she worked in the Peking Medical College Third Hospital, renamed in 2000, Peking University Third Hospital. There, she led a team of researchers and physicians in the study of human in vitro fertilization (IVF) and embryo transfer (ET) technology. Zhang and her colleagues contributed to the birth of the first test-tube baby in Mainland China in 1988.

On 10 March 1988, China's first baby conceived through human in vitro fertilization (IVF) and embryo transfer (ET), commonly referred to as a test-tube baby, was born at the Peking Hospital (PUTH) in Beijing. This birth was reported in numerous media reports as a huge step forward in China's long march to keep pace with global advances in science and technology. Led by gynecologist Zhang Lizhu, the PUTH research team had devoted more than four years to the human IVF-ET project. The team had to start by learning the basics of human egg morphology and embryology in order to design an IVF-ET strategy that was suited to the reproductive pathology affecting China's infertile population.